Clinical evidence and peer reviewed studies
TissueCypher is supported by 13 published clinical validation and utility studies that encompass one of the largest sets of Barrett's esophagus (BE) progressor patients ever assembled. In these studies, TissueCypher consistently outperforms histology and segment length as predictors of progression.
TissueCypher featured studies
Mayo Clinic Pooled AnalysisRead More
A pooled analysis of 590 patients showed that TissueCypher was a stronger predictor of progression than other clinicopathologic factors considered. For non-dysplastic patients a high-risk score was associated with an 18-fold increased risk vs. a low-risk score.
Clinical utility using the SURF cohortRead More
Tissue from 154 patents from the SURF trial was evaluated by TissueCypher as well as 30 expert and general pathologists. Care plans were evaluated with and without guidance from TissueCypher and results indicated that TissueCypher may be used to standardize management of BE patients to improve health outcomes.
Prospective Decision Impact StudyRead More
TissueCypher significantly influenced decision-making in management of patients with BE. Comparison of posttest versus pretest management recommendations showed that the TissueCypher results changed 55.0 percent of management decisions regarding surveillance intervals and therapeutic interventions.
An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus01 Nov 2023
Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.
Duits, Lucas C, et al.
A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus01 Nov 2023
This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.
Davison JM, et al.
The Tissue Systems Pathology Test Outperforms Pathology Review in Risk-Stratifying Patients with Low-Grade Dysplasia01 Nov 2023
This study aimed to compare the risk stratification performance of the TissueCypher test vs benchmarks of generalist and expert pathology.
Khoshiwal AM, et al.
A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center25 Sep 2023
TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.
Tseng D, et al.
The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort30 Aug 2023
This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.
Villa NA, et al.